my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis’ drug development programs are focused on treating cardiovascu more
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hyperc more
Genzyme Corp. and Isis Pharmaceuticals Inc. announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoin more
iCo Therapeutics Inc. announced that it has entered into a Technology Transfer Agreement with Isis Pharmaceuticals, Inc. to transfer certain technology related to the manufacture of iCo-007 to iCo in support of producing clinical grade drug product for iCo’s planned Phase II clinical program. In co more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Atherosclerosis or more
Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Rosetta Genomics, Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, more
What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more
Contact Us Business Development Future Products Lead Product Target Pre-clinical Summary Clinical Studies Technology Team Management Team Board of Directors Scientific Advisors Home News & Events Leadership in Respiratory Disease Therapy Altair Therapeutics, Inc. is a biopharmaceutical company devel more
Last: 0.425 Day Low: 0.38 Volume: 5571 Change: 0.00 Day High: 0.43 Date: 7/27/2010 Jul 26, 2010 iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007 View More + May 28, 2010 iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout G more
Contact Us Business Development Future Products Lead Product Target Pre-clinical Summary Clinical Studies Technology Team Management Team Board of Directors Scientific Advisors Home News & Events News & Events Xconomy, March 22, 2010 Searching For Signs of a Comeback in San Diego's Innovation Econom more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
